AbbVie’s Gaps Are Neurocrine’s Gains
This article was originally published in The Pink Sheet Daily
Neurocrine’s women’s health candidate, which it out-licensed to Abbott in 2010, is starting to gather steam. The candidate is benefitting from favorable data and a pressing need by Abbott spin-out, AbbVie, to succeed with its late-stage pipeline.
You may also be interested in...
In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.